DNLI
Denali Therapeutics Inc.
There isn't enough reported data to score DNLI yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DNLI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
DNLI's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DNLI PE Valuation
DNLI has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
DNLI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DNLI's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
DNLI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.73 | +$1.18 |
| Q2 2026 | -$2.84 | -$0.04 |
| Q1 2026 | -$2.88 | -$0.21 |
| Q4 2025 | -$2.97 | -$0.40 |
| Q3 2025 | -$2.91 | -$0.17 |
| Q2 2025 | -$2.80 | +$0.03 |
| Q1 2025 | -$2.67 | -$1.73 |
| Q4 2024 | -$2.57 | -$1.51 |
DNLI lost $1.73 per share over the past year, a smaller loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over DNLI on earnings quality, reporting a profit while its opponent remains loss making.
DNLI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $1.3M | -64% |
| Q2 2023 | $294.1M | +460% |
| Q1 2023 | $35.1M | -17% |
| Q4 2022 | $10.3M | -18% |
| Q3 2022 | $3.6M | -33% |
| Q2 2022 | $52.5M | +129% |
| Q1 2022 | $42.1M | +432% |
| Q4 2021 | $12.5M | -96% |
DNLI's revenue is growing: $18M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -713% | N/A |
| Q2 2026 | -3622% | N/A |
| Q3 2023 | -8981% | -5961 points |
| Q2 2023 | 58% | +175 points |
| Q1 2023 | -344% | -186 points |
| Q4 2022 | -1024% | -408 points |
| Q3 2022 | -3020% | -1401 points |
| Q2 2022 | -117% | +153 points |
DNLI's operating margin was −713% last quarter, down 369 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over DNLI on profitability, with a higher operating margin.
DNLI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$118.5M | -$12.5M |
| Q2 2026 | -$97.8M | -$18.2M |
| Q1 2026 | -$133.7M | +$2.9M |
| Q4 2025 | -$100.1M | -$11.3M |
| Q3 2025 | -$105.9M | -$42.9M |
| Q2 2025 | -$79.6M | +$16.4M |
| Q1 2025 | -$136.5M | -$20.8M |
| Q4 2024 | -$88.8M | +$12.1M |
DNLI has burned cash in almost every quarter: −$450M over the past year, against −$411M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over DNLI on cash generation, producing positive trailing cash flow while its opponent burns cash.
DNLI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +4.8M shares |
| 1 year | +11% | +19.7M shares |
| 3 years | +40% | +54.4M shares |
| 5 years | +58% | +70.3M shares |
| Available history | +100% | +96M shares |
DNLI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DNLI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -11.6x | Net Cash |
| Q2 2021 | -8.2x | Net Cash |
| Q1 2021 | -7.3x | Net Cash |
| Q4 2020 | -7.1x | Net Cash |
DNLI has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
DNLI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.5 | Neutral |
| Stochastic | 23.4 | Neutral |
DNLI's weekly RSI is 44 (neutral) and its Stochastic is 23 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DNLI PE vs Healthcare Sector
| Metric | DNLI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DNLI has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DNLI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 1.7% below |
| 20 week MA | $21.8 | 13% below |
| 50 week MA | $20.6 | 8.1% below |
| 100 week MA | $18.4 | 2.9% above |
| 200 week MA | $21.0 | 9.8% below |
DNLI's trend is mixed: it's above one of its five weekly moving averages, and 9.8% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over DNLI on trend strength, trading above more of its moving averages.
DNLI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.3 | $85.9 | +370% |
| 2021 | $85.9 | $47.5 | -45% |
| 2022 | $47.5 | $27.9 | -41% |
| 2023 | $27.9 | $21.5 | -23% |
| 2024 | $21.5 | $20.6 | -4% |
| 2025 | $20.6 | $16.9 | -18% |
| 2026 YTD | $16.9 | $18.9 | +12% |
DNLI has finished five years in a row lower, and it's up 12% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DNLI on returns for 2026, with the stronger performance.